FHI Clinical Inc. Providing Services for ACTT-1 Trial of Remdesivir for COVID-19 Treatment

FHI Clinical Inc. has announced that it has a subcontract with the Frederick National Laboratory for Cancer Research to provide clinical operations services for the Adaptive COVID-19 Treatment Trial (ACTT), a study to allow investigation of putative therapeutics, for the treatment of COVID-19 in hospitalized adults. The first iteration, from ACTT-1, included 1,063 participants recruited within an eight-week period at 60 study sites and 13 subsites from places like in Denmark, Germany, Japan, Korea, Singapore, the United States, and more. ACTT-2 is now open.

For more information, click here.